Abstract

Although our understanding of pathophysiology of asthma continues to improve, and effective antiasthma treatments are avaible, the morbidity and mortality of asthma are increasing worldwide. The primary goal of asthma management is to maintain control of disease process by reducing symptoms and asthma exacerbations and by improving lung funtion. To reach this aim, investigations about new antiasthmatic drugs are being developed. In this review, it is aimed to review the new advances in asthma therapy in details and to evaluate the new leukotrien antagonists.